Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment.
10.1016/j.apsb.2015.03.001
- Author:
Lin KANG
1
;
Zhonggao GAO
1
;
Wei HUANG
1
;
Mingji JIN
1
;
Qiming WANG
1
Author Information
1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- Keywords:
ANG-CLP, angiopep-2 modified cationic liposome;
CMC, critical micelle concentration;
CPLA, cationic polylactide;
Chemotherapeutic drug;
Co-delivery;
DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane;
Dendrimer;
FA, folic acid;
FCAP, ferrocenium capped amphiphilic pillar[5]arene;
GSH, glutathione;
Gene;
Liposome;
Micelle;
Nanocarrier;
OEI, oligoethylenimine;
PAMAM, poly(amido amine);
PAsp(AED), poly(N-(2,2ʹ-dithiobis(ethylamine))aspartamide);
PCL, poly(ε-caprolactone);
PDMAEMA, polydimethylaminoethyl methacrylate;
PDPA, poly(2-(diisopropyl amino)ethyl methacrylate);
PEG, polyethyleneglycol;
PEI, poly(ethyleneimine);
PEI-Fc, ferrocene modified poly(ethyleneimine);
PEI-PCHLG, poly(ethylene imine)-poly(γ-cholesterol-l-glutamate);
PEI-PCL, poly(ethyleneimine) and poly(ε-caprolactone);
PLA, polylactic acid (or polylactide);
PLGA, poly(lactic-co-glycolic acid);
PPEEA, poly(2-aminoethyl ethylene phosphate);
PnBA, poly(n-butyl acrylate);
RNAi, RNA interference;
SNPs, supramolecular nanoparticles;
SSTRs, somatostatin receptors poly(N-(2,2′-dithiobis(ethylamine))aspartamide);
Supramolecular system;
miRNA, micro-RNA;
siRNA, small interfering RNA;
siVEGF, VEGF-targeted siRNA;
γ-CD, γ-cyclodextrin
- From:
Acta Pharmaceutica Sinica B
2015;5(3):169-175
- CountryChina
- Language:English
-
Abstract:
The efficacy of chemotherapeutic drug in cancer treatment is often hampered by drug resistance of tumor cells, which is usually caused by abnormal gene expression. RNA interference mediated by siRNA and miRNA can selectively knock down the carcinogenic genes by targeting specific mRNAs. Therefore, combining chemotherapeutic drugs with gene agents could be a promising strategy for cancer therapy. Due to poor stability and solubility associated with gene agents and drugs, suitable protective carriers are needed and have been widely researched for the co-delivery. In this review, we summarize the most commonly used nanocarriers for co-delivery of chemotherapeutic drugs and gene agents, as well as the advances in co-delivery systems.
